anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The dramatic increase in opioid prescriptions over the past years has been linked to the concomitant rise in opioid addiction and to deaths from opioid abuse. Young adults' initial exposure to opioid analgesics is often following extraction of their impacted third molars, with an average of 5,000,000 cases in the USA per year. Over-prescribing of opioids for surgical pain, often 2-5 times more than patients actually use, further exacerbates this problem, as patients tend to save leftover pills rather than discard them. Up to 70% of individuals who become addicted to prescription opioids had access to leftover pills prescribed for others. This is particularly troubling as the odds of transitioning to heroin from prescription opioid abuse are much higher than other suspected gateway drugs, about 40 fold greater than non-gateway drug users. Heroin is now often laced with fentanyl derivatives making overdose and death more likely in even the most opioid tolerant individuals.

Multiple studies have demonstrated that non-addicting nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac are effective in relieving pain after dental impaction surgery, being at least equally efficacious to optimal doses of immediate release opioid formulations combined with acetaminophen. However, these assessments of pain relief represent average scores and approximately 22% and 50% of individuals required additional opioid-containing rescue analgesics when ibuprofen and diclofenac were employed at FDA-approved dosages. A deeper understanding of the sources of variability in pain relief should allow improvements in the overall efficacy of NSAIDs by targeting treatment to those who are most likely to receive sufficient pain relief. Thus, optimizing pain therapy with NSAIDs by personalization would be expected to help limit the unnecessary prescription of highly addicting immediate release opioids. Moreover, these results may have applicability to other types of pain that are driven by inflammation.
Described herein are compositions and compounds having one or more aziridinyl groups, and methods of making the same. The compounds can also have one or more nitrogen atoms that each can be positively charged. The composition and compounds can inactivate one or more nucleic acid molecules (e.g. a DNA and/or a RNA from a pathogen) in a sample. The sample can comprise a blood or blood product (e.g., donated blood). The compositions and compounds can inactivate any nucleic acid present in a blood or blood product, thereby making the blood or blood product safe for use (e.g., in a transfusion).
This is an open, prospective, quasi-randomized, single center trial that will address the primary research question: Does use of a colorimetric carbon dioxide (CO2) detector (Pedi-Cap) decrease the duration of non-invasive positive pressure ventilation (PPV) in the delivery room? The neonatal resuscitation team, comprised of nurses, doctors, and respiratory therapists will include or omit the use of Pedi-Cap during noninvasive PPV for infants born at ≥30 weeks' gestation in the delivery room. The quasi-randomization scheme will be determined by a randomizer for each month. This will be revealed at the beginning of each month on whether to use Pedi-Cap or not. Other outcomes variables that will be assessed include initial heart rate (HR), time to HR \> 100 bpm, duration of bradycardia, time to start of ventilation corrective maneuvers (if needed), maximum peak inspiratory pressure used, time to gold color change on Pedi-Cap, need for intubation, need for delayed PPV, need for chest compressions/epinephrine, need for neonatal intensive care unit admission if infant ≥35 gestational age, occurrence of pneumothorax, length of mechanical ventilation in days, and need for surfactant. Infant and maternal characteristics will be obtained from the electronic medical record. Association of outcomes with each study arm will be stratified by infant and maternal characteristics.

In addition, a survey will be administered to the resuscitation team members at the completion of the study to assess their experience with each study arm.
Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include beta-hydroxybutyrate (BHB), analogs thereof, and GPR 109 A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions, such as citrate. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions. Certain formulations enable convenient administration of the beneficial combination product in powdered form for mixing with liquid. Such formulations can be salt-balanced, and may be free of sodium and/or silicates, and are well tolerated. The formulations may be provided in a container and measuring implement to enable convenient measurement of dosages.
A dual power device and scanning apparatus employing the same are described. The scanning apparatus includes a detecting module, a switch unit, and a power controller. The detecting module detects a first voltage signal and a second voltage signal for generating a detecting signal. The switch unit receives the commands from the power controller for outputting the first and/or the second voltage signals to the image acquiring device of the scanning apparatus. The power controller determines whether the first voltage signal is generated. While the first voltage signal is generated, the power controller controls the switch unit to output the first voltage signal and/or the second voltage signal to the image acquiring device. While the first voltage signal is not generated, the power controller controls the switch unit to output the second voltage signal to the image acquiring device.
A dispenser including a first dispensing portion including one group of storage units for each of ten to twenty-eight days, and a second dispensing portion, including at least one storage unit for each of seventeen to thirty days. In the first dispensing portion, a first set includes a group of four storage units for each day, a second set includes a group of three storage units for each day, and a third set includes a group of two storage units for each day. The first dispensing portion contain a progestin. In the second dispensing portion, the first fourteen storage units contain a placebo and the remaining storage units contain a progestin. First and second dispensing portions may be provided as separate dispensing packs, or as a multi-pack of second dispensing portions. The dispenser is useful for treatment of acute episodes of dysfunctional uterine bleeding (DUB) and maintenance treatment for preventing future episodes of DUB.
Tablets are packed in discontinuous pockets formed at certain distances from each other between two continuous strips of packing material; the individual pockets are formed by hot welding. In the new packing the tablets are essentially rectangular in shape and so made that they can be received into a pocket which is smaller than that required hitherto for a normal rectangular tablet. The tablet consists of a small platelet obtd. by the compression of a suitable compsn. with a punch in a die of corresponding shape; the two opposite principal faces have a convex form which is partly spherical. Each of the principal faces is delimited by four curved edges connected by rounded corners. The lateral faces have an ellipsoidal form. In the packed assembly, the dimensions of each pocket in the packing material, such as paper, sheet aluminium or regenerated cellulose, are only slightly larger than the tablets because of the convexity of their principal faces; no shapr edges exist which might pierce the walls of the pocket.
During alcohol cue exposure, a placebo tDCS is used with electrodes placed over the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2). There is a 20 second ramp going up until 2 mA and back to 0 again at the beginning and the end of the placebo stimulation with no active stimulation during the cue exposure.
The invention relates to a method to inhibit gene expression in bacteria, which is referred to here as Antibacterial Gene Silencing (AGS). In particular embodiments, the method is used to protect plants and animals against pathogenic bacteria by targeting pathogenicity factors and / or essential genes in a sequence-specific manner via small non-coding RNAs. The method can also be used to enhance beneficial effects and / or growth of symbiotic or commensal bacteria. The invention involves the exogenous delivery of small RNA entities onto bacteria, either in the form of RNA extracts or embedded into plant extracellular vesicles (EVs), so as to reduce bacterial growth, survival and / or pathogenicity. The invention also describes a method to identify in a rapid, reliable and cost-effective manner, small RNAs that possess antibacterial activity and that have the potential to be further developed as anti-infective agents. In addition, the latter method is instrumental to rapidly characterize any gene from any bacterial species.
Participants in the experimental group will receive the Mindfulness-Based Breastfeeding Programme, which consists of six 30-minute sessions within 0-72 hours. They will also be asked to complete a personal information form. In addition to the hospital sessions, educational materials, including home applications and audio recordings, will be sent via WhatsApp after discharge. During the first week after discharge, counselling will be provided by phone or WhatsApp on the continuation of mindfulness-based practices, continuation of breastfeeding and problems related to breastfeeding, and referral to the health facility in case of problems, "Iowa Infant Feeding Attitude Scale" and "Mindful Breastfeeding Scale" will be administered by phone call in the 2nd month and finally the "Infant Feeding Follow-up Form" prepared by the researcher based on the literature will be used to assess the continuity of breastfeeding in the 1st week, 2nd month, 4th month and 6th month.
The invention provides methods of preparing a cell therapy by collecting fluid from a site proximal to a tumor and expanding T cells obtained from the fluid. Methods include collecting fluid from a site proximal to a tumor, obtaining at least one T cell from the fluid, and culturing the T cells in vitro. The fluid may be collected during or after surgical removal of a tumor from the site of the surgical removal of the tumor. The fluid may be drain fluid that drains from a surgical site. The method may include diverting the fluid from a waste disposal protocol or vessel in a surgical theater and into a collection vessel. Preferably the fluid includes lymphatic fluid.
Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention belongs to the field of traditional Chinese medicine preparations, and particularly relates to a foot bath medicine composition for treating senile insomnia and a preparation method thereof. The foot bath medicine composition for treating senile insomnia is prepared from the following raw materials in parts by weight: 15 parts of ginseng, 20 parts of schisandra chinensis, 5 parts of fructus amomi, 5-20 parts of monkshood, 10 parts of tortoise shell, 20 parts of oyster and 15 parts of honey-fried licorice root. The foot bath medicine composition for treating senile insomnia provided by the invention is compatible for use, and can regulate yin and yang, soothe nerves, help sleep and communicate heart and kidney. Ginseng can supplement primordial qi of the elderly and five internal organs; fructus Schisandrae chinensis has effects in tonifying kidney and calming heart; radix Aconiti lateralis Preparata can supplement fire of Mingmen, dispel cold in kidney, and fructus Amomi can descend floating qi; tortoise shell and oyster are used to replenish essence and suppress yang, and prepared licorice root is used to tonify middle-jiao. The medicines are combined to supplement the deficiency of primordial qi of old people, warm the kidney, astringe yin and replenish essence to help sleep. Compared with the medicine taking, the product does not damage liver and kidney, has no toxic or side effect, has good clinical curative effect, has high content of effective components after the medicine is extracted, is easier to dissolve and is very convenient to use.
A topical hair care formulation and method of making includes combining generally equal amounts of  eclipta alba  herbal powder and  embelica officinalis  herbal powder to form a herbal powder mixture. The herbal powder mixture is steeped in an amount of base oil for a period of time to form a brown solution. A portion of an amount of olive oil is combined with an amount of biotin and an amount of Methylsulfonylmethane to form a natural mixture. A remainder of the amount of olive oil is combined with the brown solution. An amount of jojoba oil is combined with the brown solution. An amount of rosemary oil is combined with the brown solution. An amount of lavender oil is combined with the brown solution. The natural mixture is combined with the brown solution. The brown solution is settled for a period of time to form the topical hair care formulation.
Vaccination schedules 5 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
An acupoint positioning system and an acupoint positioning method are provided. The acupoint positioning system includes a server system and an electronic device. The server system stores predetermined human body model data. The electronic device captures a human body part image and transmits the human body part image to the server system. The server system calibrates the predetermined human body model data based on human body size data of the human body part image, and, based on a calibration result, generates human body model data that includes a human body massage part and at least one piece of human body massage positioning data located at the human body massage part. The server system transmits the human body model data to the electronic device that displays the human body model data.
With the objective of validating the efficacy and safety of physical exercise as a therapeutic resource in patients admitted for decompensated heart failure; will be applied, by rehabilitation nurses, a protocol of physical exercise, with increasing levels of intensity. Patients who meet the inclusion criteria will be randomized through an online program (randomizer.org) and the ERIC protocol will be applied to the test group. The control group will be implemented the usual care of rehabilitation nursing. The ERIC protocol comprises 5 levels of intensity, as following shown: Stage 1 - respiratory and calisthenic exercises (5-10 minutes) Stage 2 - pedal for 5-10 minutes Stage 3 - aerobic training: walking on the corridor for 5-10 minutes Stage 4 - aerobic training: walking on the corridor for 10-15 minutes Stage 5 - aerobic training: walking on the corridor for 15 minutes + climbing stairs for 5 minutes All patients will be monitored and followed up by a rehabilitation nurse while they are doing the exercise. The investigator decides, depending on the patient's performance and clinical conditions, the form of progression in the program, but it is mandatory to follow the previously defined levels of intensity.

Patients in the test group may start the program only on stage I or II according to clinical criteria. At admission of the patients (test group and control group) clinical and sociodemographic parameters are evaluated, as well as data related to Barthel's indices and London Chest of activities of daily living (LCADL). At the discharge date, the Barthel index and the LCADL scale will also be evaluated, as well as the 6-minute walking test.
Currently, it is acknowledged that gout is caused by uric acid (UA). However, some studies have revealed no correlation between gout and UA levels, and growing evidence suggests that 2,8-dihydroxyadenine (2,8-DHA), whose structural formula is similar to UA but is less soluble, may induce gout. Hence, we hypothesized that uroliths from hyperuricemia (HUA) patients, which is closely associated with gout, may contain 2,8-DHA. In this study, 2,8-DHA in uroliths and serum of HUA patients were determined using HPLC. Moreover, bioinformatics was used to investigate the pathogenic mechanisms of 2,8-DHA nephropathy. Subsequently, a mouse model of 2,8-DHA nephropathy established by the gavage administration of adenine, as well as a model of injured HK-2 cells induced by 2,8-DHA were used to explore the pathogenesis of 2,8-DHA nephropathy. Interestingly, 2,8-DHA could readily deposit in the cortex of the renal tubules, and was found in the majority of these HUA patients. Additionally, the differentially expressed genes between 2,8-DHA nephropathy mice and control mice were found to be involved in inflammatory reactions. Importantly, CCL2 and IL-1β genes had the maximum degree, closeness, and betweenness centrality scores. The expressions of CCL2 and IL-1β genes were significantly increased in the serum of 24 HUA patients with uroliths, indicating that they may be significant factors for 2,8-DHA nephropathy. Further analysis illustrated that oxidative damage and inflammation were the crucial processes of 2,8-DHA renal injury, and CCL2 and IL-1β genes were verified to be essential biomarkers for 2,8-DHA nephropathy. These findings revealed further insights into 2,8-DHA nephropathy, and provided new ideas for its diagnosis and treatment.
The device under test was the Prizma which is a phone cover biometric device that includes reflectance oximetry. This device is a spot checker that requires the patient to hold their finger on the sensor during the measurement. The subjects were asked not to move during the study. In order to get consistent measurements the fingers were taped to the test device. The tape acted mainly as a reminder, and there were some problems with finger movement. A radial arterial cannula was placed in either the left or right wrist of each subject.

Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1). Each subject had control data taken at the beginning of each experiment, with two control blood samples drawn while breathing room air. Hypoxia was induced to different levels of oxyhemoglobin saturation (between 70-100%) by having subjects breathe mixtures of nitrogen, room air, and carbon dioxide. Oxyhemoglobin saturation was reduced to a series of targets and stabilized at the plateau value. Each plateau level of oxyhemoglobin saturation was maintained for at least 30 seconds. Two arterial blood samples were then obtained, approximately 30 seconds apart. A total of 24 samples were obtained per subject. Data were recorded by Bickler-Ye lab and provided for analysis.
This study will be conducted at the Lung Center of the Philippines. The study design is a retrospective case series implemented via chart review. Online and written patient records will be reviewed to determine the baseline patient characteristics and the preoperative outcomes. Patients who recovered from COVID-19 will be selected from those who underwent anatomic lung resection from June 1, 2020 to May 31, 2022. This study will be done in accordance with the Helsinky Declaration and Good Clinical Practice Guidelines, and will be subject for approval of the institutional Ethics and Technical Review Boards. Descriptive statistics will be used to describe patient characteristics and perioperative outcomes.
Disubstituted bicyclic heterocycles of the Formula (I) in particular for inhibiting thrombin and prolonging thrombin time. The disclosed compounds relates to the tautomers, stereoisomers, mixtures, and salts, which have valuable properties. The compounds of the above general formula (I), in which E is a cyano group, represent valuable intermediate products for the production of the other compounds of the general formula (I). Furthermore, the compounds of the above general formula (I), in which E stands for a RbNH-C(=NH)-group, have valuable pharmacological properties.  Wherein;  A denotes a carbonyl or sulphonyl group linked to benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno moiety of the group Het.  B denotes an ethylene group, in which a methylene group, linked to either to the group Het or Ar, may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, carbonyl or -NR1- group, wherein  	R1 denotes a hydrogen atom or C1-5alkyl group;  E denotes an RbNH-C(=NH)-group wherein  	Rb denotes a hydrogen atom, hydroxy group, C1-3alkyl or C1-3alkoxy group;  Ar denotes a phenylene group optionally substituted by fluorine, chlorine or bromine atom or by trifluoromethyl, C1-3alkyl or C1-3alkoxy group; a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted by C1-3alkyl group;  Het denotes a bicyclic heterocycle of the formula (II), (III), (IV), (V), (VI), (VII) or (VIII);  Ra denotes C1-6alkyl group, C3-7cycloalkyl group optionally substituted by C1-3alkyl group. Ra is further described as disclosed.
This is an international, multicenter, non-interventional, retrospective study to evaluate the efficacy and safety of bortezomib in 100 adult patients diagnosed with multiple myeloma (MM) who responded to bortezomib as first-line treatment, experienced partial response or better, presented with relapsed disease, and were re-treated (second-line) with bortezomib (for at least 3 cycles) after a treatment-free interruption of at least 6 months. As this is a non-interventional study, no changes to the current treatment that the patient receives will be required, and no additional treatment will be provided by the company. The decision of the patients to take part in this study will not have any impact on the care they receive. All the appropriate treatment-related decisions will have been made by the treating physician(s), and only data available from clinical practice will be collected. Retrospective data will be collected at a single time point for each patient (the data collection visit). Each investigator should collect data from patients fulfilling all inclusion and exclusion criteria. After receiving the signed informed consent form (ICF) from the patient (if required by local regulations), the investigator will start documenting the retrospective data for each patient using electronic data capture (eDC). After confirmation of the patient's eligibility, the patient's last visit, patient characteristics, predefined risk factors (if available), MM-related data, and first- and second-line bortezomib-related data will be documented in the Case Report Form (CRF). The patient's status after re-treatment with bortezomib, medical resource utilization data, as well as (serious) adverse drug reactions (\[S\]ADRs) will be collected. No blood, urine, or other biological samples will be taken, and no additional investigations will be performed. the current therapy of the patient will be maintained with no changes